HC Wainwright Begins Coverage on BioDelivery Sciences International, Inc. (BDSI)

HC Wainwright started coverage on shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in a research report released on Sunday. The brokerage issued a buy rating and a $5.00 price target on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. FBR & Co set a $4.00 target price on BioDelivery Sciences International and gave the company a buy rating in a report on Tuesday, May 16th. Zacks Investment Research cut BioDelivery Sciences International from a buy rating to a hold rating in a report on Monday, July 17th. ValuEngine cut BioDelivery Sciences International from a hold rating to a sell rating in a report on Friday, September 1st. Cantor Fitzgerald restated an overweight rating and issued a $4.50 target price on shares of BioDelivery Sciences International in a report on Monday, August 14th. Finally, Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the company a buy rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $4.21.

BioDelivery Sciences International (NASDAQ BDSI) opened at 3.00 on Friday. BioDelivery Sciences International has a 1-year low of $1.50 and a 1-year high of $3.60. The stock has a market capitalization of $166.43 million, a price-to-earnings ratio of 107.14 and a beta of 1.04. The firm’s 50-day moving average is $3.18 and its 200 day moving average is $2.43.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). The company had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $8.45 million. BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The firm’s quarterly revenue was up 74.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.31) earnings per share. Equities analysts anticipate that BioDelivery Sciences International will post $0.12 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2887637/hc-wainwright-begins-coverage-on-biodelivery-sciences-international-inc-bdsi.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC grew its holdings in shares of BioDelivery Sciences International by 22.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock worth $9,737,000 after purchasing an additional 632,853 shares during the period. EAM Investors LLC purchased a new position in shares of BioDelivery Sciences International during the 2nd quarter worth $1,348,000. Advisor Group Inc. grew its holdings in shares of BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after purchasing an additional 13,341 shares during the period. Northern Trust Corp grew its holdings in shares of BioDelivery Sciences International by 0.9% during the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after purchasing an additional 1,203 shares during the period. Finally, GSA Capital Partners LLP grew its holdings in shares of BioDelivery Sciences International by 10.1% during the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock worth $1,369,000 after purchasing an additional 44,700 shares during the period. Institutional investors and hedge funds own 41.44% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.